Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Trial Profile

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Fluorocyclopentenylcytosine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 22 Jan 2019 According to a Rexahn Pharmaceuticals media release, the company expects to complete the study enrollment and to report additional efficacy data later this year.
    • 22 Jan 2019 Preliminary Data (N=24) presented in a Rexahn Pharmaceuticals Media Release.
    • 19 Jan 2019 Preliminary results (n=21, data cut off: 21 Sep 2018) presented at the 2019 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top